Literature DB >> 33290624

Increased Rates of Obstetric Complications Prior to Systemic Sclerosis Diagnosis.

Melody P Chung1, Kathleen D Kolstad2, Makdine Dontsi3, Debbie Postlethwaite3, Poonam Manwani4, Hongyu Zhao4, Sumana Kesh4, Julia F Simard2, Lorinda Chung5.   

Abstract

OBJECTIVE: To investigate whether obstetric complications prior to systemic sclerosis (SSc) diagnosis are more common in SSc patients compared to the general obstetric population.
METHODS: A case-control study was performed at Kaiser Permanente Northern California to compare prior obstetric complications in adult women who later developed SSc (cases) with women from the general obstetric population who did not develop SSc (controls; matched 10:1 by age and year of delivery) from 2007 to 2016. Exposures included past hypertensive disorders of pregnancy (preeclampsia, eclampsia, gestational hypertension), premature rupture of membranes (PROM), intrauterine growth restriction (IUGR), maternal infections, neonatal intensive care unit (NICU) admission, and preterm birth. Fischer's exact tests were used to compare categorical variables. Conditional logistic regression models estimated the odds ratio (OR), and corresponding 95% confidence intervals (95% CIs) for the outcome SSc.
RESULTS: Seventeen SSc cases and 170 non-SSc controls were identified, with median maternal age at delivery 34 years (range 23-46 years) and median time from delivery to SSc diagnosis 2 years (range 0.2-7.3 years). Women with SSc were more likely to be Hispanic and Black. Prior obstetric complications appeared higher in women with an eventual SSc diagnosis compared to controls (70.6% versus 50%), including hypertensive disorders (17.7% versus 9.4%), PROM (11.8% versus 4.1%), IUGR (5.9% versus 1.8%), maternal infection (29.4% versus 14.1%), NICU admissions (23.5% versus 7.7%), and preterm delivery (29.4% versus 21.8%). Women with SSc had a higher odds of delivering infants requiring NICU admission (OR 4.7 [95% CI 1.2-18.8]).
CONCLUSION: Women who eventually develop SSc had trends toward more complicated pregnancy histories before overt diagnosis.
© 2020 American College of Rheumatology.

Entities:  

Mesh:

Year:  2022        PMID: 33290624      PMCID: PMC8184883          DOI: 10.1002/acr.24533

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   5.178


  15 in total

Review 1.  Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis.

Authors:  Lazaros I Sakkas; Ian C Chikanza; Chris D Platsoucas
Journal:  Nat Clin Pract Rheumatol       Date:  2006-12

2.  Pregnancy in Systemic Sclerosis: Results of a Systematic Review and Metaanalysis.

Authors:  Jelena Blagojevic; Khitam Abdullah AlOdhaibi; Aly M Aly; Silvia Bellando-Randone; Gemma Lepri; Cosimo Bruni; Alberto Moggi-Pignone; Serena Guiducci; Federico Mecacci; Marco Matucci-Cerinic; Daniel E Furst
Journal:  J Rheumatol       Date:  2019-09-01       Impact factor: 4.666

3.  Microchimerism and HLA-compatible relationships of pregnancy in scleroderma.

Authors:  J L Nelson; D E Furst; S Maloney; T Gooley; P C Evans; A Smith; M A Bean; C Ober; D W Bianchi
Journal:  Lancet       Date:  1998-02-21       Impact factor: 79.321

4.  Outcome of pregnancies complicated by systemic sclerosis and mixed connective tissue disease.

Authors:  L Chung; R L R Flyckt; I Colón; A A Shah; M Druzin; E F Chakravarty
Journal:  Lupus       Date:  2006       Impact factor: 2.911

5.  The impact of unrecognized autoimmune rheumatic diseases on the incidence of preeclampsia and fetal growth restriction: a longitudinal cohort study.

Authors:  Arsenio Spinillo; Fausta Beneventi; Elena Locatelli; Vèronique Ramoni; Roberto Caporali; Claudia Alpini; Giulia Albonico; Chiara Cavagnoli; Carlomaurizio Montecucco
Journal:  BMC Pregnancy Childbirth       Date:  2016-10-18       Impact factor: 3.007

6.  Quantification of fetal microchimeric cells in clinically affected and unaffected skin of patients with systemic sclerosis.

Authors:  H H B Sawaya; S A Jimenez; C M Artlett
Journal:  Rheumatology (Oxford)       Date:  2004-06-15       Impact factor: 7.580

7.  Male microchimerism in healthy women and women with scleroderma: cells or circulating DNA? A quantitative answer.

Authors:  Nathalie C Lambert; Y M Dennis Lo; Timothy D Erickson; Tracy S Tylee; Katherine A Guthrie; Daniel E Furst; J Lee Nelson
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

8.  Preeclampsia and scleroderma: a prospective nationwide analysis.

Authors:  Mads Kamper-Jørgensen; Hilary S Gammill; J Lee Nelson
Journal:  Acta Obstet Gynecol Scand       Date:  2018-02-08       Impact factor: 3.636

9.  Increased incidence of pregnancy complications in women who later develop scleroderma: a case control study.

Authors:  Linda van Wyk; Jacolien van der Marel; Annemie J M Schuerwegh; Anne A Schouffoer; Alexandre E Voskuyl; Tom W J Huizinga; Diana W Bianchi; Sicco A Scherjon
Journal:  Arthritis Res Ther       Date:  2011-11-04       Impact factor: 5.156

10.  What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Population-Based Study of Maternal and Fetal Outcomes in SLE and Pre-SLE.

Authors:  Elizabeth V Arkema; Kristin Palmsten; Christopher Sjöwall; Elisabet Svenungsson; Jane E Salmon; Julia F Simard
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-07       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.